Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Novo Nordisk A/S ADR
(NY:
NVO
)
146.91
+4.63 (+3.25%)
Official Closing Price
Updated: 7:00 PM EDT, Jun 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Novo Nordisk A/S ADR
< Previous
1
2
3
4
5
6
7
8
9
...
48
49
Next >
EXCLUSIVE: GameStop, AMC Buzz 'May Prove To Be Short-Lived,' CEO Of Company Behind MEME ETF Tells Benzinga
May 17, 2024
The company behind the MEME ETF shares what it would take to bring the meme stock fund back to the market.
Via
Benzinga
Topics
ETFs
Pharma Stocks Outlook: Where Are 2024’s Top Performers Headed Next?
May 17, 2024
Investors want to know where 2024's top-performing pharma stocks are headed in the second half of the year for good reason.
Via
InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
May 17, 2024
Via
Benzinga
Smart Money Is Betting Big In NVO Options
May 17, 2024
Via
Benzinga
Here's How Much You Would Have Made Owning Novo Nordisk Stock In The Last 10 Years
May 16, 2024
Via
Benzinga
Should Quality Investors Include NYSE:NVO in Their Portfolio?
May 16, 2024
Is NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) suited for quality investing?
Via
Chartmill
Spotlight on Novo Nordisk: Analyzing the Surge in Options Activity
May 14, 2024
Via
Benzinga
Elevai Labs (NASDAQ: ELAB) Acquires Rights To Develop Muscle Loss Prevention Assets For Anticipated Use In Anti-Obesity Treatments, Launches Two New Subsidiaries
May 17, 2024
Elevai Labs (NASDAQ: ELAB) Acquires Rights To Develop Muscle Loss Prevention Assets For Anticipated Use In Anti-Obesity Treatments, Launches Two New Subsidiaries
Via
News Direct
Meet the GLP-1 Drug That Could Be the Biggest Concern for Eli Lilly and Novo Nordisk
May 17, 2024
Could Amgen be the next stock to soar due to a GLP-1 drug?
Via
The Motley Fool
7 Pharma Stocks Harnessing AI Brainpower for Big Breakthroughs
May 16, 2024
AI continues to impact pharma stocks to buy in a major way, with these shares particularly well positioned as things heat up.
Via
InvestorPlace
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Patent Peril: 3 Stocks at Risk From the FTC’s Drug Crusade
May 16, 2024
The FTC is putting these three drug stocks at risk by trying to strip their therapies of protection from generics.
Via
InvestorPlace
Topics
Intellectual Property
Exposures
Intellectual Property
No Wegovy Shortage in Denmark Amid High Demand, Novo Nordisk Confirms
May 15, 2024
Novo Nordisk confirms there is no anticipated shortage of Wegovy in Denmark, despite prior warnings from the Danish Medicines Agency about limited supplies. The company addresses high demand and...
Via
Benzinga
If You'd Invested $1,000 in Novo Nordisk Stock 5 Years Ago, Here's How Much You'd Have Today
May 15, 2024
Back then, the company wasn't very well known to U.S. investors. That's absolutely not the case these days.
Via
The Motley Fool
Eli Lilly Strikes Deal To Combat Counterfeit Diabetes And Weight Loss Drugs Mounjaro And Zepbound
May 15, 2024
Eli Lilly has settled with Totality Medispa over counterfeit Mounjaro and Zepbound sales. The spa will pay damages and cease using Lilly branding. Corrective measures include compliance with federal...
Via
Benzinga
Novo Nordisk Bets Up to $600 Million on Ozempic 2.0. Here's Why the Stock Is a Buy.
May 15, 2024
This company is serious about maintaining its leadership.
Via
The Motley Fool
2 Top Pharma Stocks That Just Keep Getting Better and Better
May 14, 2024
Both of these businesses are finding traction in a pair of major markets.
Via
The Motley Fool
Novo Nordisk's Wegovy Delivers: Long-Term Study Shows Sustained Weight Loss As Drugmaker Tries To Woo Insurers And Governments
May 14, 2024
The data could potentially bolster Novo's case for Wegovy as it attempts to convince insurers and governments to cover the cost of the drug.
Via
Benzinga
Novo Nordisk's Hemophilia Candidate Can Prevent Bleeding Episodes Effectively, Regardless Of Dosing Frequency
May 13, 2024
Novo Nordisk's Phase 3a trial demonstrates a significant reduction in bleeding episodes with Mim8 treatment for hemophilia A patients. Superior efficacy and safety profile revealed.
Via
Benzinga
How Viking Therapeutics Stock Could 30x
May 13, 2024
This mid-cap biopharma may one day be a titan of the industry.
Via
The Motley Fool
The Must-Watch List: 3 Stocks to Snap Up as Soon as They Hit Bargain Territory
May 13, 2024
These three companies could soon be the next bargain stocks to buy as the market adjusts to their developing situations.
Via
InvestorPlace
Billionaire Jim Simons Owns These 2 Healthcare Stocks: Should You?
May 12, 2024
These stocks are both experts in their respective fields.
Via
The Motley Fool
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever.
May 11, 2024
These pharmaceutical companies are top-notch dividend growth stocks for the future.
Via
The Motley Fool
7 Stocks That Ordinary Investors Can’t Get Enough Of Right Now
May 10, 2024
While people tend to be too cool for school regarding groupthink, these popular stocks among retail investors could change perceptions.
Via
InvestorPlace
Can Weight Loss Companies Fuel Gains In Your Stock Portfolio?
May 09, 2024
Analysts predict the weight loss drug market could reach $100 billion by the end of the decade, with millions of patients potentially using these medications. However, challenges remain.
Via
Talk Markets
10 Health Care Stocks With Whale Alerts In Today's Session
May 09, 2024
Via
Benzinga
7 Weight Loss Drug Stocks Poised for Explosive Growth by 2025
May 09, 2024
The second wave of the weight loss drug stock boom is underway and investors should heed the signs the market is serving.
Via
InvestorPlace
3 Million Reasons Novo Nordisk Still Looks Like a Phenomenal Buy
May 09, 2024
This is a stock you shouldn't hesitate to buy on the dip.
Via
The Motley Fool
Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare
May 07, 2024
Investors concerned about broader market undulations may want to consider the resilience narrative of these biotech stocks to buy.
Via
InvestorPlace
Investors should take note of NYSE:NVO, a growth stock that remains attractively priced.
May 07, 2024
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) is showing decent growth, but is still valued reasonably.
Via
Chartmill
'Ozempic Ftw:' Elon Musk Touts Novo Nordisk's Blockbuster Drug As Solution To Childhood Obesity Problem
May 05, 2024
This is not the first time the tech mogul has seemingly backed the blockbuster drug. Last year, Musk claimed that Ozempic was affecting food sales at Walmart.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
48
49
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.